Recombinant DNA×Cell biology

The Frontier Brief for this collision is still being written. The evidence below already reflects the current model run.

Pre-company space. No named players have staked this collision yet — an emerging pairing where the field, not a firm, is the story so far.

89 researchers publish on both sides of this collision without the fields themselves having met. Every name below is counted from papers in the corpus — not inferred.

• Alexandra LeopoldiLaboratoire d'Électronique des Technologies de l'Information
  1/3
• Eduard AyusoCentre d'Investigation Clinique de Nantes
  3/1
• Josef PenningerUniversité Grenoble Alpes
  1/3
• Alexander M. MakhovPenn State Milton S. Hershey Medical Center
  1/2
• Reiner WimmerBoehringer Ingelheim (Austria)
  1/2
• Mario MietzschUniversity of Florida
  1/2
• Guangping GaoThe University of Melbourne
  2/1
• Robert McKennaUniversity of Florida
  1/2
• Ron WeissRagon Institute of MGH, MIT and Harvard
  1/2
• James F. ConwayPenn State Milton S. Hershey Medical Center
  1/2

• Harvard UniversityUS
  8/217
• Howard Hughes Medical InstituteUS
  4/154
• InsermFR
  7/72
• Centre National de la Recherche ScientifiqueFR
  5/91
• Massachusetts Institute of TechnologyUS
  5/89
• Broad InstituteUS
  4/101

• Anticodon-edited transfer RNAs (ACE-tRNAs) encoded as therapeutic nonviral minimal DNA vectors2026 · 3 citations · DOI ↗
  2
• 546. Development of MFP-Inducible System for AAV5 Gene Therapy of Chronic Diseases in the Liver2016 · 0 citations · DOI ↗
  2
• Microfluidic-enhanced 3D bioprinting of aligned myoblast-laden hydrogels leads to functionally organized myofibers in vitro and in vivo2017 · 331 citations · DOI ↗
  4
• Cloaking nanoparticles with protein corona shield for targeted drug delivery2018 · 409 citations · DOI ↗
  3

Counted from the corpus. Institution counts use best-effort affiliation (every author on a paper is paired with every institution on it), so read them as presence, not headcount.